Print

Purpose

This study compares p-tau217 concentrations in blood collected via the Tasso device versus standard venipuncture in subjects with and without Alzheimer's disease, including a subset with confirmed amyloid pathology.

Conditions

Eligibility

Eligible Ages
Between 40 Years and 90 Years
Eligible Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • AD Amyloid PET/CSF confirmed, healthy control, or amyloid-negative non-AD cognitive impairment Age 40-90 Able to complete Tasso and venipuncture collection Caregiver consent/assistance available if needed

Exclusion Criteria

  • Uncontrolled systemic conditions Recent surgery/hospitalization (3 months) Other dementia drug trial (2 months) Pregnancy Prior Donanemab or Lecanemab use

Study Design

Phase
Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Arm Groups

ArmDescriptionAssigned Intervention
AD subjects Amyloid PET/CSF confirmed and clinically diagnosed
Healthy Controls No history of cognitive impairment
Non-AD cognitively impaired (amyloid-negative) Cognitive impairment not due to AD, confirmed amyloid-negative via PET/CSF

Recruiting Locations

Insigth Hospital and Medical Center Chicago
Chicago, Illinois 60616
Contact:
Ansam Eghzawi, MD
+18109410076
ansam@neurogenbiomarking.com

More Details

Status
Recruiting
Sponsor
Neurogen Biomarking LLC

Study Contact

Ansam Eghzawi, MD
+18109410076
ansam@neurogenbiomarking.com

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.